PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 132 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,272,950 | +22.7% | 136,268 | +103.1% | 0.06% | -1.7% |
| Q2 2023 | $1,853,136 | -25.7% | 67,094 | -38.1% | 0.06% | -24.7% |
| Q1 2023 | $2,494,879 | -99.9% | 108,473 | -53.4% | 0.08% | +108.1% |
| Q3 2022 | $1,963,000,000 | +12.9% | 232,820 | +5.9% | 0.04% | +48.0% |
| Q2 2022 | $1,739,000,000 | – | 219,820 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |